PL370361A1 - Alkyl urea retinoid agonists i - Google Patents

Alkyl urea retinoid agonists i

Info

Publication number
PL370361A1
PL370361A1 PL02370361A PL37036102A PL370361A1 PL 370361 A1 PL370361 A1 PL 370361A1 PL 02370361 A PL02370361 A PL 02370361A PL 37036102 A PL37036102 A PL 37036102A PL 370361 A1 PL370361 A1 PL 370361A1
Authority
PL
Poland
Prior art keywords
cancer
alkyl urea
emphysema
retinoid agonists
dermatological disorders
Prior art date
Application number
PL02370361A
Other languages
English (en)
Polish (pl)
Inventor
Paula Nanette Belloni
Denis John Kertesz
Michael Klaus
Jean-Marc Lapierre
Original Assignee
F.Hoffmann-La Roche Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F.Hoffmann-La Roche Ag filed Critical F.Hoffmann-La Roche Ag
Publication of PL370361A1 publication Critical patent/PL370361A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C275/00—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
    • C07C275/28—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C275/42—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton being further substituted by carboxyl groups
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/04—One of the condensed rings being a six-membered aromatic ring
    • C07C2602/10—One of the condensed rings being a six-membered aromatic ring the other ring being six-membered, e.g. tetraline

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
PL02370361A 2001-09-18 2002-09-11 Alkyl urea retinoid agonists i PL370361A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US32296301P 2001-09-18 2001-09-18

Publications (1)

Publication Number Publication Date
PL370361A1 true PL370361A1 (en) 2005-05-16

Family

ID=33130243

Family Applications (1)

Application Number Title Priority Date Filing Date
PL02370361A PL370361A1 (en) 2001-09-18 2002-09-11 Alkyl urea retinoid agonists i

Country Status (13)

Country Link
US (1) US6844466B2 (enExample)
EP (1) EP1430024A1 (enExample)
JP (1) JP4421293B2 (enExample)
KR (1) KR100896550B1 (enExample)
CN (1) CN1283621C (enExample)
AR (1) AR036533A1 (enExample)
AU (1) AU2002329276B2 (enExample)
BR (1) BR0212583A (enExample)
CA (1) CA2460693C (enExample)
MX (1) MXPA04002590A (enExample)
PL (1) PL370361A1 (enExample)
RU (1) RU2299877C2 (enExample)
WO (1) WO2003024921A1 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2004251712A1 (en) * 2003-06-23 2005-01-06 Auspex Pharmaceuticals, Inc. Novel therapeautic agents for the treatment of cancer, metabolic diseases and skin disorders
WO2005108338A1 (en) * 2004-05-03 2005-11-17 Auspex Pharmaceuticals Novel therapeutic agents for the treatment of cancer, metabolic diseases and skin disorders
CN101146763A (zh) * 2005-03-30 2008-03-19 默克公司 胰高血糖素受体拮抗剂化合物、含有这种化合物的组合物以及使用方法
TW200821284A (en) * 2006-10-03 2008-05-16 Merck & Co Inc Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use
CN111773213B (zh) 2010-09-01 2023-02-24 托马斯杰弗逊大学 用于肌肉修复和再生的组合物和方法
WO2014073209A1 (ja) 2012-11-08 2014-05-15 国立大学法人山口大学 角結膜障害の治療剤
KR101426197B1 (ko) * 2013-02-20 2014-08-01 여윤영 주먹밥틀
US10702502B2 (en) 2013-05-22 2020-07-07 Yamaguchi University Inhibitor for retinochoroidal disorders
CN105294567B (zh) * 2015-10-29 2018-10-09 湖北新烯王生物科技有限公司 取代的3-氟苯基甲醇类化合物、药物组合物及用途
ES2963348T3 (es) 2016-06-08 2024-03-26 Clementia Pharmaceuticals Inc Métodos para tratar la osificación heterotópica
JP7018957B2 (ja) 2016-11-16 2022-02-14 クレメンティア ファーマシューティカルズ インコーポレイテッド 多発性骨軟骨腫(mo)を処置するための方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LU87821A1 (fr) 1990-10-12 1992-05-25 Cird Galderma Composes bi-aromatiques,et leur utilisation en medecine humaine et veterinaire et en cosmetique
DE69333894D1 (de) * 1992-04-22 2005-12-01 Ligand Pharm Inc Verbindungen mit Retinoid x rezeptorselektivität
US6093742A (en) 1997-06-27 2000-07-25 Vertex Pharmaceuticals, Inc. Inhibitors of p38
JO2178B1 (en) * 1999-10-19 2003-04-23 اف . هوفمان لاروش ايه جي Treatment of emphysema using rar selective retinoid antagonists

Also Published As

Publication number Publication date
AU2002329276B2 (en) 2008-04-24
BR0212583A (pt) 2004-10-13
CN1555359A (zh) 2004-12-15
MXPA04002590A (es) 2004-06-18
CA2460693C (en) 2010-12-07
JP4421293B2 (ja) 2010-02-24
RU2299877C2 (ru) 2007-05-27
US20030158226A1 (en) 2003-08-21
RU2004111787A (ru) 2005-10-20
AR036533A1 (es) 2004-09-15
WO2003024921A1 (en) 2003-03-27
CN1283621C (zh) 2006-11-08
JP2005505571A (ja) 2005-02-24
CA2460693A1 (en) 2003-03-27
US6844466B2 (en) 2005-01-18
EP1430024A1 (en) 2004-06-23
KR20040035809A (ko) 2004-04-29
KR100896550B1 (ko) 2009-05-07

Similar Documents

Publication Publication Date Title
MY141661A (en) 17b-hydroxysteroid dehydrogenase type 3 inhibitors for the treatment of androgen dependent diseases
AU2003256755A1 (en) Ureido substituted benzoic acid compounds, their use for nonsense suppression and the treatment of diseases caused by such mutations
MXPA03011515A (es) Nuevas composiciones de medicamentos sobre la base de agentes anticolinergicos, corticoesteroides y agentes betamimeticos.
JO2434B1 (en) New retinoids to treat emphysema
MXPA04002070A (es) Compuestos de indazol sustituidos para el tratamiento de la inflamacion.
IL162214A (en) Pyridine derivatives and pharmaceutical compositions containing the same
PL360495A1 (en) Arylmethylamine derivatives for use as tryptase inhibitors
WO2002100347A3 (en) Prodrugs of gaba analogs, compositions and uses thereof
WO2004043341A3 (en) Treatment for hemorrhagic shock
AU8830801A (en) Use of derivatives of valproic acid amides and 2-valproenic acid amides for the treatment or prevention of pain and/or headache disorders
MEP54608A (en) Arylmethylamine derivatives for use as tryptase inhibitors
MXPA03010761A (es) Combinaciones farmaceuticas.
MY141528A (en) Anilinopyrazole derivatives useful for the treatment of diabetes
GB0002336D0 (en) Medicaments
DE60205899D1 (en) 1-biaryl-1,8-naphthyridin-4-one als phosphodieseterase-inhibitoren
TW200505443A (en) Combination of SCR kinase inhibitors and chemotherapeutic agents for the treatment of proliferative diseases
AU4179399A (en) Use of nmda antagonists and/or sodium channel antagonists for the treatment of inflammatory disorders
MXPA04003611A (es) Piperidina- y piperazinacetaminas como inhibidores de la 17 beta-hidroxiesteroide deshidrogenasa tipo 3 para el tratamiento de enfermedades androgeno-dependientes.
WO2004073615A8 (en) Deazaflavin compounds and methods of use thereof
GB9907571D0 (en) Compounds
PL370459A1 (en) Substituted urea retinoid agonists ii
BR0212583A (pt) Agonistas i para retinóides de alquil uréia
BR0008603A (pt) Método para tratamento de copd
WO2002041831A3 (en) Inositol derivatives for increasing chloride secretion and inhibiting inflammation
PT1567139E (pt) Nova combinação sinérgica compreendendo roflumilaste e formoterol

Legal Events

Date Code Title Description
VOID Decisions declaring the decisions on the grant of the patent lapsed